FindTrial
Sign In

OSE2101

DRUG4 trials

Sponsors

OSE Immunotherapeutics, GERCOR - Multidisciplinary Oncology Cooperative Group, ARCAGY/ GINECO GROUP

Conditions

Locally Advanced CancerMetastatic CancerNon Small Cell Lung CancerPancreatic Ductal AdenocarcinomaPatients With Non-Small Cell Lung CancerPlatinum-sensitive Ovarian CancerRelapsed Ovarian Cancer

Phase 2

OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC
Active, not recruitingNCT03806309
GERCOR - Multidisciplinary Oncology Cooperative GroupLocally Advanced Cancer, Metastatic Cancer, Pancreatic Ductal Adenocarcinoma
Start: 2021-04-10End: 2025-12-31Target: 106Updated: 2025-07-25
OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC
Active, not recruitingNCT04713514
ARCAGY/ GINECO GROUPPlatinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
Start: 2021-08-05End: 2025-12-31Target: 180Updated: 2024-12-02

Phase 3

OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure
TerminatedNCT02654587
OSE ImmunotherapeuticsNon Small Cell Lung Cancer
Start: 2016-02-12End: 2021-01-15Updated: 2024-02-02
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
RecruitingNCT06472245
OSE ImmunotherapeuticsPatients With Non-Small Cell Lung Cancer
Start: 2024-12-03End: 2028-12-15Target: 363Updated: 2026-07-23

Related Papers

Phase 3 trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy.
Journal of Clinical Oncology2025-05-281 citations
Maintenance with OSE2101 plus FOLFIRI vs FOLFIRI alone after FOLFIRINOX (FFX) induction in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): Primary endpoint results of a randomized TEDOPAM GERCOR D17-01 PRODIGE 63 trial.
Journal of Clinical Oncology2025-05-281 citations
TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer
Future Oncology2024-08-19
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab vs best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.
Journal of Clinical Oncology2023-06-013 citations
Prognostic factors of overall survival (OS) in non-small cell lung cancer (NSCLC) patients after failure on immune checkpoint inhibitors (IO) treated with anticancer vaccine OSE2101 or chemotherapy (CT) in phase 3 ATALANTE-1 randomized trial.
Journal of Clinical Oncology2023-06-01
A randomized, non-comparative, phase II study of maintenance OSE2101 vaccine alone or in combination with nivolumab (nivo) or FOLFIRI after induction with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC): First interim results of the TEDOPAM GERCOR D17-01 PRODIGE 63 STUDY.
Journal of Clinical Oncology2022-06-013 citations
TEDOVA/GINECO-OV244b/ENGOT-ov58 trial: Neo-epitope based vaccine OSE2101 alone or in combination with pembrolizumab versus best supportive care (BSC) as maintenance in platinum-sensitive recurrent ovarian cancer with disease control after platinum.
Journal of Clinical Oncology2022-06-012 citations
Quality of life (QoL) of OSE2101 in patients with HLA-A2+ non–small cell lung cancer (NSCLC) after failure to immune checkpoint inhibitors (IO): Final data of phase 3 Atalante-1 randomized trial.
Journal of Clinical Oncology2022-06-011 citations
366 Combined exploratory immunophenotyping and transcriptomic tumor analysis in patients treated with OSE2101 vaccine in HLA-A2+ advanced non-small cell lung cancer (NSCLC) from the ATALANTE-1 trial
Regular and Young Investigator Award Abstracts2021-11-01
ATALANTE-1 randomized phase III trial, OSE 2101 versus standard treatment as second- or third-line in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients.
Journal of Clinical Oncology2019-05-202 citations
A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM–PRODIGE 63 GERCOR D17-01 study).
Journal of Clinical Oncology2019-05-20